Stefan D. Anker

机构：Brigham and Women's Hospital, Harvard University, Wroclaw Medical University, Deutsches Herzzentrum der Charité, Berlin-Brandenburger Centrum für Regenerative Therapien, German Centre for Cardiovascular Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Deutsches Herzzentrum München, Berlin Heart (Germany), Bayer (Germany), Charité - Universitätsmedizin Berlin · ORCID：0000-0002-0805-8683

发表论文 1187 篇 · 总被引 147676 次 · h-index 166

代表论文

• SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria (2025 · JAMA · 被引 57)
• Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria (2025 · JAMA · 被引 16)
• A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD (2025 · Kidney International Reports · 被引 6)
• Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes (2025 · Journal of the American College of Cardiology · 被引 3)
• Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials (2025 · Diabetes Obesity and Metabolism · 被引 3)
• Target-dose vs below-target-dose ACE inhibitors and lower risk of kidney failure and mortality in US Veterans with HFrEF (2026 · European Journal of Heart Failure · 被引 1)